Obermatt
See Similar Stocks →

Cybin

NEO:HELP · CA23256X4075
PharmaceuticalsSmall

360° View

no current rank
Price/Sales—
Price/Earnings30
Price/Book60
Dividend Yield1
Revenue Growth—
Profit Growth93
Capital Growth28
TSR 52w8
Leverage88
Liquidity22
Refinancing92
Combined—
Analyst Opinions100
Pro Holdings37
Opinion Changes50
Market Pulse88

Profile

CountryCanada
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Employees78
Websitehelus.com
ISINCA23256X4075
Last UpdateApr 2, 2026
Index & Theme
AddictionNeurologyPsychiatryCentral Nervous SystemNeurosciencePsychedelic-Based TherapyBiotechnologyHealth CareMental HealthPharmaceutical

Description

Cybin Inc. operates as a clinical-stage breakthrough neuropsychiatry company. The company is developing CYB003, a proprietary deuterated psilocin molecule for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecul…

Similar Stocks

The companies this stock is ranked against.

Compare Cybin with its peers
Rapport Therapeutics
NMQ:RAPP
13
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Neumora Therapeutics
NSQ:NMRA
9
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Cognition Therapeutics
NAQ:CGTX
—
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Aardvark Therapeutics
NSQ:AARD
29
CountryUSA
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Definium Therapeutics
NSQ:DFTX
22
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →